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Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is inadequate. Autologous
stem cell transplantation is a relatively eﬀective treatment, but residual malignant sites may cause relapse. Allogeneic transplanta-
tion may result in durable responses due to antitumour immunity mediated by donor lymphocytes. However, morbidity and
mortality related to graft-versus-host disease remain a challenge. Recent advances in understanding the interaction between the
immune system of the patient and the malignant cells are inﬂuencing the design of clinically more eﬃcient study protocols for
MM. Cellular immunotherapy using speciﬁc antigen-presenting cells (APCs), to overcome aspects of immune incompetence in
MMpatients,hasreceivedgreatattention,andnumerousclinicaltrialshaveevaluatedthepotentialfordendriticcell(DC)vaccines
as a novel immunotherapeutic approach. This paper will summarize the data investigating aspects of immunity concerning MM,
immunotherapyforpatientswithMM,andstrategies,ontheway,totargettheplasmacellmoreselectively.WealsoincludetheMM
antigens and their speciﬁc antibodies that are of potential use for MM humoral immunotherapy, because they have demonstrated
the most promising preclinical results.
1.Introduction
In spite of recent advances [1, 2], MM remains an incurable
disease, and new approaches that induce long-term tumor
regression and improve disease outcome are needed.
Autologous stem cell transplantation is a common treat-
ment for MM and results in eﬀective cytoreduction. How-
ever, the curative outcome remains elusive due to chemo-
therapy-resistant disease [3]. A promising route to overcome
chemotherapyresistanceisthedevelopmentofimmunother-
apeutic approaches that target and eliminate myeloma cells
more selectively.
A critical indication that immunotherapy is eﬀective is
that tumor-associated antigens (TAAs) are expressed in the
tumor cells if disease reemerges after therapy. Vaccination
strategiestargetingsingleantigensandwhole-cellapproaches
have shown promise in clinical studies.
They also have the advantage of presenting patient-spe-
ciﬁc and potentially unidentiﬁed antigens to immune eﬀec-
tor cells.
Monoclonal antibodies (mAbs) have been evaluated in
preclinical and clinical studies. Potential mAb candidates in-
clude growth factors and their receptors, other signalling
molecules, and antigens expressed exclusively or predomin-
a n t l yo nM Mc e l l s .T h e r a p yw i t hm A bm a yi n v o l v ear a n g e
of mechanisms, including antibody-dependent cellularcyto-
toxicity(ADCC),complement-dependentcytotoxicity(CDC),
interferencewithreceptor-ligandinteractions,andmAbcon-
jugation to radioisotopes or toxins [4].
Eﬀector cell dysfunction and the increased number of re-
gulatory T cells in patients with malignancy may limit the ef-
ﬁcacy of immunotherapeutic approaches. Strategies to im-
prove immunotherapy for MM involve the depletion of T2 Clinical and Developmental Immunology
regulatory cells, combining active and passive immunother-
apy,theuseofcytokineadjuvants,andusingimmunotherapy
in conjunction with autologous and allogeneic transplanta-
tion.
The unique value of immunotherapy, in allogeneic trans-
plantation,isthegraft-versus-diseaseeﬀectmediatedbyallo-
reactive lymphocytes, which attack the tumor.
However, the signiﬁcant morbidity and mortality due to
regimen-relatedtoxicityandgraft-versus-hostdisease(GvHD)
pertain [5].
Immunotherapy is promising area of investigation that
focusesondevelopingstrategiestoelicitmyeloma-speciﬁcim-
mune responses to eliminate the malignant plasma cell
selectively.
2.Tumor-Speciﬁc ImmunityandImmune
Evasion:The Role of the Adoptive and
InnateImmune SysteminControlling MM
MMisassociatedwithavarietyofimmunedefects;therefore,
immunotherapy is particularly challenging. It is considered,
at least to a certain extent, to be controlled by the adaptive
immune system. This hypothesis is supported by the fact
that the therapeutic eﬀect of alloSCT is mediated in part by
immune eﬀects exerted by donor-derived T cells and that
donor T cells infused into MM patients are capable of in-
ducing remission in case of relapse [6, 7].
The development of eﬀective tumor-speciﬁc immuno-
therapy requires addressing several basic issues concerning
tumorcellbiologyandthecomplexinteractionbetweencan-
cer cells and host immunity.
Tumor cells may evade host immunity through a variety
ofmechanisms.Somemaycontributetomyelomacell“toler-
ance,” including myeloma-derived cytokines such as trans-
forming growth factor-b (TGF-b), which suppresses B cells
and T cells via inhibition of interleukin-2 (IL-2) autocrine
pathways, inadequate antigen presentation, resistance to NK
cell lysis, and defective T, B, and NK cells [8]. Much data sug-
gests that early-stage cancers are eliminated by immune sur-
veillance, whereas established tumors are more likely to in-
duce immune tolerance [9].
Tumor-speciﬁc CD4+ T cells have a central function in
the immune response against cancer [10, 11]. Early studies
in rats and mice indicated that adoptive transfer of tumour-
speciﬁc CD4+ T cells may be very eﬃcient in eradicating
established cancers [12, 13]. CD4+ T cells are required for
activation of tumour-speciﬁc cytotoxic CD8+ T cells [14],
but they can also eradicate cancer in the absence of CD8+
T cells [15, 16]. Tumor-speciﬁc CD4+ T cells recognize
antigenic peptides presented by MHC class II molecules.
However, most cancer cells are MHC class II negative and
therefore cannot be directly recognized by CD4+ T cells.
Tumor-speciﬁc CD4+ T cells overcome this obstacle by
collaborating with macrophages and dendritic cells [17].
These professional antigen-presenting cells endocytose TSA,
process it, and display antigenic peptides on their MHC class
II molecules for recognition by tumor-speciﬁc CD4+ T cells
[10, 18, 19]. The number and function of T cell subsets
were reported to be abnormal in patients with MM. The
CD4:CD8 ratio inverted, and the Th1:Th2 ratio among
C D 4 +c e l l si sa b n o r m a l[ 20]. T cells from MM patients were
shown to function aberrantly [21]. In addition, the levels of
expression of CD28 and cytotoxic T lymphocyte-4 (CTLA-4)
costimulatory molecules required for T cell activation and
inhibition, respectively, were downregulated in T cells deri-
ved from MM patients [22]. Tumor cells express a variety
of factors that suppress the function and development of
APCs and T cells. The B7 family of cosignaling molecules
is expressed on the surface of T lymphocytes and is crucial
for their optimal activation, as well as for the prevention of
immunologic tolerance. These cosignaling molecules not
only provide critical positive signals that stimulate T cell
growth, upregulate cytokine production, and promote T cell
diﬀerentiation but also contribute key negative signals that
limit, terminate, and/or attenuate T cell responses [23, 24].
Although the antibodies may trigger direct antitumor
activity through their Fab2 portion causing apoptosis of
tumor cells [25], they more often mediate damage of can-
cer cells by recruiting other eﬀector systems of innate immu-
nity through their Fc portion. Such eﬀector cells include
mononuclear and polymorphonuclear leukocytes that pha-
gocytise opsonized tumor cells and NK cells primarily in-
volvedintheprocessofADCC[26].Complementistheother
soluble eﬀector system of innate immunity that can be re-
c r u i t e db ym A b st oc o n t r o lt u m o rg r o w t hC D C C[ 27, 28].
Theroleofinnateeﬀectorcells,suchasmacrophages,NK
cells, NKT cells, and γδT cells, in natural tumor immunity
and tumor immunotherapy has been revisited [29, 30]. NK
cells are cytotoxic lymphocytes that have the ability to lyse
certain tumor and virus-infected cells, without prior immu-
nization [31]. The cytotoxic activity of NK cells is tightly
controlled by a balance between activating and inhibitory
signals from receptors on the cell surface [32]. Activating re-
ceptors include the natural cytotoxicity receptors and
NKG2D, all of which push the balance toward cytolytic ac-
tion through engagement with separate ligands on the target
cell surface [32]. The role of autologous NK cells in the im-
mune recovery, which is a strong prognostic indicator for
survival after autologous stem cell transplantation (ASCT),
was highlighted by Porrata et al. [33], who showed that re-
infusion ofautologousNKcellscorrelateswithabsolute lym-
phocyte recovery after ASCT for MM and non-Hodgkin’s
lymphoma.
Defective NK cells have also been noted in patients with
MM [34]. This is of major importance since NK cells have
antimyeloma activity [35, 36]. In the setting of AlloSCT for
MM, there is emerging evidence that donor NK cells along
with donor Tlymphocytes exhibit anti-MM activity [37]. In
another study, it was shown that, after coincubation of NK
cells from normal volunteers with myeloma cells from three
diﬀerent MM cell lines and fresh BM samples from nine
myeloma patients, myeloma cells were susceptible to NK cell
lysis, even in the absence of IL-2 [36]. Of note, CD34 he-
matopoietic stem cells, as well as peripheral blood mononu-
clear cells (PBMNCs), were completely resistant to NK cell
killing under similar conditions [36]. Recently, it has been
shown that autologous NK cells from myeloma patientsClinical and Developmental Immunology 3
expanded ex vivo with IL-2 displayed signiﬁcant cytotox-
ic activity against primary autologous plasma cells [38].
Furthermore, it has been demonstrated that the infusion
of haploidentical killer-cell immunoglobulin-like receptor
(KIR) ligand-mismatched NK cells in the autologous MM
setting resulted in 50% near complete remission of relapsed
MM patients [39]. However, ex vivo or in vivo expansion of
the NK cells with IL-2 carries a dose-limiting toxicity.
The role of dendritic cells (DCs) is dichotomous; they
may present both antigens, appropriate stimulator molecules
to initiate an adaptive immune response, or they may induce
tolerance and release anti-inﬂammatory signals. Circulating
DCs from MM patients were shown to be dysfunctional be-
cause they failed to upregulate costimulatory molecules re-
quired for activation [40]. It was suggested that a reduced
function of DCs indicates the progression of the disease
[40]. Cytokines, such as IL-6, TGF-b, IL-10, and vascular
endothelial growth factor (VEGF), which were actively pro-
duced by myeloma cells [40]a n dw e r ef o u n dt ob ei nt h e
tumormicroenvironmentaswellasintheserum[41],played
a role in preventing the development of functional DCs. Fur-
thermore, DCs from MM patients had reduced phagocytic
capacity [42]. In addition, monocyte-derived DCs exhib-
ited downregulated expression of activation markers and
impaired presentation capacity to T cells [41]. Impaired ac-
tivity of DCs may be linked to the upregulation of Tregs [43].
T cell tolerance to tumor-associated antigens plays a signif-
icant role in immune evasion by tumors [44, 45]. Naturally
occurring and adaptive regulatory T cells (Tregs) are anergic
cells with suppressive capabilities that constitute 5–10% of
CD4 cells. These cells are induced early during tumor devel-
opment and were shown to contribute to tumor tolerance
[46, 47].
The presence of Tregs in tumors is associated with a poor
prognosis [48]. Patients with many diﬀerent types of cancers
had increased numbers of Tregs in their blood, tumor mass,
and draining lymph nodes [49, 50]. Increased numbers of
Tregs were found in patients with MM as well [51–53]. Ther-
apeuticapproachesforbreakingtolerancetotumorcellshave
been tried; the depletion of Tregs is the most studied strategy
[54–56].Nevertheless,despitethetumorantigen-speciﬁcim-
munity [57], the tumors were not completely rejected [58].
Thus, it is essential to reveal the mechanism leading to Treg
expansion for developing strategies to eliminate them and to
improve the results of cancer immunotherapy [59].
There is also emerging evidence that the cellular bone
compartment aﬀects MM cell growth and progression. This
is supported by the observation that osteoclasts can support
long-term survival and proliferation of primary MM cells
[60, 61], and osteoblasts (OB) may impede MM cell growth
[62, 63]. Thus, targeting these cellular elements may also
favorably aﬀect disease control. The BM microenvironment
in MM controls the tumor growth, myeloma cell survival
[64]anddrugresistance[65,66].Inturn,MMcellsweresug-
gested to modify the BM microenvironment in which they
reside in several ways including induction of osteoclasto-
genesis and suppression of osteoblast activity, both leading
to impaired bone formation [67]. BM-derived mesenchymal
stromal cells (MSCs) are precursors of osteoblasts and pref-
erentially diﬀerentiate into bone forming cells upon in vitro
culture and in vivo introduction. MM cells were suggested
to target MSCs thereby diverting their functions to serve the
MM cells. This idea led to studies of the functions of MSCs
derived from MM patients (MM-derived MSCs) compared
to those of healthy individuals; it was suggested that MSCs
from myeloma patients exhibit defective functions [68–
70]: MM-derived MSCs were reported to exhibit decreased
colony-forming unit number [70], growth impairment [70],
reduced osteogenic diﬀerentiation [68] and increased IL-6
secretion [68, 70].
To summarize, the task of developing eﬀective immuno-
therapy for cancer relies on the identiﬁcation of appropriate
tumor targets, the augmentation of antigen-presenting and
eﬀectorcellfunction,andthereversalofthetumor-mediated
immunosuppressive state [71]. In this review we focus on
MM antigens and their speciﬁc antibodies, which have de-
monstrated the most promising results in preclinical studies
and are therefore the best candidate for future MM humoral
immunotherapy.
3. Myeloma-Speciﬁc Antigensand Vaccines:
Idiotype—PreclinicalStudies
The myeloma-speciﬁc antigen that can be targeted by immu-
notherapy is the idiotype (Id) protein representing the vari-
able segment of the monoclonal immunoglobulin generated
in the plasma cell clone [72]. Targeting of the idiotype pro-
tein by humoral or cellular immune mechanisms, in preclin-
ical models, results in death of the tumor cells and disease
regression. Induction of protective antitumor immunity
through immunization with a myeloma idiotype has been
most extensively studied with the murine plasmacytoma
MOPC-315 model. In this model, it was shown that weekly
immunizations with tumor-derived paraprotein protect syn-
geneic mice against a subsequent challenge with MOPC-315
cells [73]. Idiotype-speciﬁc T cells at a low frequency were
detected in 90% of patients with MM or MGUS [74, 75].
In addition, transfer of idiotype-speciﬁc CD4+ T cells has
been shown to be protective against tumor challenge [76].
Antigen-speciﬁc responses, of both CD4 and CD8 positive T
cells, upon in vitro stimulation with autologous paraprotein
have been described in patients with monoclonal gammo-
pathies [74]. Induction of cytotoxic T cell activity against
autologous myeloma cells was also shown for stimulation
withidiotype-loaded dendritic cells[77,78].Consistentwith
these results, several authors have shown that T cells in my-
eloma patients respond to peptides corresponding to com-
plementarity-determining region I–III of heavy and light
chains of the autologous M-component [79, 80]. Yi found
[81] that idiotype-induced T cell stimulation was mainly
conﬁned to the CD4+ subset in most of the patients ex-
amined and was MHC class II restricted. Idiotype-speciﬁc
CD8+ T cells were also demonstrated, but at a lower freq-
uency.Idiotype-speciﬁcCD4+andCD8+Tcellsweremainly
of the type 1 subsets, as judged by their secretion of inter-
feron (IFN)-γ and interleukin (IL)-2 [82, 83]. Moreover, the
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of the T-helper-1 (Th1) type (IFN-γ- and/or IL-2-secreting
cells) [84] was signiﬁcantly higher for patients with indolent
disease (MGUS and MM stage I) than for those with ad-
vancedMM(stageII/III).Incontrast,cellssecretingtheTh2-
subtypecytokineproﬁle(IL-4only)[84]wereobservedmore
frequently in patients with advanced MM (stage II/III) [75].
Collectively, these ﬁndings indicate that the existing
idiotype-speciﬁc immune response is too weak to controlthe
growth of myeloma cells in vivo. It is possible that a shift
from an idiotype-speciﬁc type-1 response, that is, Th1 and
Tc y t o t o x i c - 1( T c 1 )[ 85], in early MM to a type 2 response




Native idiotype protein can be obtained from the serum of
myeloma patients, making vaccination trials relatively easy.
Injectionofparaproteinalonemayleadtoanincreasedcellu-
lar and humoral immune responses, but it seems insuﬃcient
to generate sustained antimyeloma immunity [86]. Intrader-
mal injections of paraprotein, combined with subcutaneous
administration of GM-CSF at the same site, induced an
increase in the numbers of IFNγ- and IL-2-secreting T cells
[87]. This response was present in CD4+ and CD8+ T cell
subsets and could be inhibited by blockade of MHC class
I molecules. Furthermore, production of idiotype-speciﬁc
IgM was induced in vivo. However, there was no clear in-
dication of clinical eﬃcacy since the paraprotein levels re-
mained essentially unchanged, and DTH (delayed-type hy-
persensitivity reaction) responses to idiotype protein were
not detected.
In contrast, in subcutaneous vaccination with keyhole
limpet haemocyanin (KLH)-coupled paraprotein and addi-
tionaladjacentinjectionsofGM-CSFinpatientsafterahigh-
dose chemotherapy and ASCT, DTH reactions to the vaccine
wereinducedin85%ofpatients,butinvitrotestingprovided
little evidence for speciﬁc T cell immune responses [88, 89].
A potential concern with the use of idiotype-based vac-
cination approaches in MM is that plasma cells only express
the idiotype protein weakly, and idiotype may be associated
withthedevelopmentoftolerance.Onestrategyfortargeting
myeloma by host eﬀector cells is the genetic manipulation of
T cells such that the idiotype antibody is expressed and in-
duces signalling via the T cell receptor.
When patients in stage I disease were immunized with
idiotype inconjunctionwithIL-12+/− GM-CSF, therewasa
decrease in circulating clonal cells as detected by quantitative
PCRmonitoringinfourofsixpatients[90].Finally,intrader-
mal immunization with uncoupled recombinant idiotype in
conjunction with GM-CSF induced idiotype-speciﬁc T cell
reactivity in a patient with advanced myeloma [91].
Idiotype-loaded dendritic cells (DCs) have been used by
various groups as vaccines in MM patients, mostly in the
settingofclinicalremissionafterautoSCT[92–96].Although
the patient characteristics and vaccine particularities pre-
clude ﬁrm comparisons between these trials, they neverthe-
less have collectively shown that the induction of cellular
immune responses is possible in the setting of minimal dis-
ease burden after ASCT. However, no real evidence has been
obtained in these Phase I and II trials that the natural course
of the disease has been altered by idiotype vaccination, and
eﬀorts to improve the immunogenicity of the vaccination are
ongoing.
5.Myeloma-SpeciﬁcTumor Antigens
A variety of tumor-associated antigens have been identiﬁed
in myeloma cells that may be targeted selectively by the im-
munity of the host. These include the cancer testis (CT) anti-
gens, MUC1, HM1.24, CYP1B1, SP17, PRAME, Wilms’ tu-
mour 1 (WT1), and heat shock protein gp96 [97–102].
MUC1 is a physiologically highly glycosylated epithelial
mucin. Since the molecule is often expressed but severely
underglycosylated on malignant cells, it may be recognized
by cytotoxic T cell lymphocyte (CTL) toxicity in a MHC-un-
restricted manner [103]. This eﬀect has also been shown in
myeloma [104]. Furthermore, HLA class-I-restricted peptide
target epitopes have also been identiﬁed within the MUC1
sequence, and the majority of myelomas appear to express
and present these epitopes to T cells [97].
WT1 is a zinc ﬁnger transcription factor with overex-
pression in myeloid malignancies [105, 106]. While WT1 is
also frequently expressed, albeit at lower level, in lymphoid
malignancies, myeloma cells may be eﬃciently recognized
and lysed by WT1-speciﬁc CTL [107].
CD317/HM1.24, a cell surface protein involved in cell
signaling [108], is another potential tumor-associated anti-
gen overexpressed in MM [109]. HM1.24-speciﬁc CTL can
be induced in healthy volunteers and MM patients [110].
Recently, it has been shown that the pituitary tumor
transforming gene 1 is expressed aberrantly in multiple my-
eloma and may serve as a target for cellular immunotherapy
[111].
TheRHAMMisanimmunogenicantigenthatisstrongly
expressed in several hematologic malignancies [112, 113]
and induces humoral and cellular immune responses [114–
119].
CT antigens represent a family of proteins that are ex-
pressedinavarietyoftumors,whiletheirpresenceinnormal
tissueislimitedtothetestisandplacenta.Severalgroupshave
described that CT antigens are also expressed by myeloma
cells [98, 120–125].
CT antigens are commonly capable of inducing anti-
body-mediated and T cell-mediated immunity in MM pa-
tients [100]. CT Ag-speciﬁc T cells can be detected in the
blood of myeloma patients and appear to be functionally
competent [124, 126]. Depending on the patient population
and the method used to detect CT gene expression, there
appears to be a trend towards higher likelihood of expression
with advanced stage [121, 123] and presence of cytogenetic
abnormalities [124], both representing adverse prognostic
factors in myeloma. These antigens represent potential ma-
rkers for minimal residual disease (MRD) after ASCT and
could also be used to target myeloma cells remaining in the
patients’ BM after standard therapy. In addition, in MM,Clinical and Developmental Immunology 5
expression of CT antigens has been shown to be strongly
correlated to the clinical outcome; that is, the presence of CT
antigensexpressionhasbeenlinkedtoshortersurvival[127].
Baseline expression frequencies, measured by RT-PCR,
determined MAGE-C1/CT7 as the most frequently detected
antigen, possibly perform a gatekeeper function for the other
antigens examined. Importantly, 80% of the patients with a
signiﬁcant number of plasma cells expressed at least one of
these antigens investigated [128].
A novel CT antigen, ropporin, is a testis-speciﬁc protein
localized in the sperm ﬂagella. Comparing ropporin expres-
sion in healthy and MM samples, ropporin expression posi-
tive signals were found in 44% of the MM primary samples.
The immunogenicity of ropporin wasconﬁrmed by the pres-
enceofspeciﬁcantibodiesdetectedbyenzyme-linkedimmu-
nosorbent assay in patients’ serum [129].
ThegeneexpressionofCTantigeninrelapsesamplesand
in newly diagnosed MM cases was evaluated [130, 131]. The
CT antigen expression after treatment was shown for a lim-
ited number of CT antigens including PASD1, CTAG1B,
and MAGEC1/CT7 [123, 124, 128, 132, 133]. Multivariate
analysis demonstrated that for the set of newly diagnosed
casesshorteroverallsurvivalwasassociatedwiththepresence
of MAGEA6 and CDCA1, and MAGEA9 was associated with
a shorter overall survival in [130]. In the set of the relapse
cases, the presence of CTAG2 was associated with a shorter
progression free-survival and the presence of SSX1 with
shorter overall survival [130].
NY-ESO-1 is the most immunogenic of the CT antigens
[99]. NY-ESO-speciﬁc CTLs generated from patients with
MM were shown to kill primary myeloma cells, normal cells
pulsed with a NY-ESO-1 peptide, but not normal cells puls-
ed with an irrelevant peptide. Spontaneous humoral and
CD8− T cell-mediated responses to NY-ESO-1 have been id-
entiﬁed in patients with advanced disease [99, 124, 126].
VaccinationstrategiestargetingNY-ESO-1maybeeﬀectiveat
inducing speciﬁc antimyeloma immunity, and a clinical trial
evaluating the eﬃcacy of an NY-ESO peptide vaccination
given in conjunction with GM-CSF is underway [99].
Importantly, the ﬁnding that immune responses against
CT antigens are induced by alloSCT [100] suggests that this
class of tumor antigens might indeed represent natural
targets for donor-derived alloimmune or even spontaneous
antimyeloma immune responses. Interestingly, in patients
undergoing an allogeneic transplantation, antibody respons-
es to NY-ESO-1 were detected after transplantation, suggest-
ing that this may represent a target for the graft-versus-my-
eloma eﬀect. LAGE-1 mRNA was detected in 49% of MM
patients [134]. Recently, de Carvalho et al. reported that
LAGE-1a mRNA was more frequent than LAGE-1b expres-
sion in MM cases [135]. The LAGE-1a protein has 84% simi-
larity with the NY-ESO-1 protein, and the authors identiﬁed
seven peptides present in both CTAs that were recognized
by T lymphocytes in diﬀerent tumors. Because spontaneous
humoral immunity against NY-ESO-1 was not detected
before the allogeneic transplant in previous study [100], the
LAGE-1a isoform and NY-ESO-1 could be considered as one
“single” CTA for immunotherapy purposes [135].
Currently, an immunotherapy trial targeting the CTAs
MAGE-A3 and NY-ESO-1 in MM patients is in progress
(NCT00090493).
6.Cell-BasedMyelomaVaccines
Instead of vaccinating myeloma patients against TAs, an
alternative principle aims at stimulating the immune system
with the entirety of the myeloma cell’s antigens [136]. Such
approaches may be implemented by using tumor cell lysates
or apoptotic tumor cells as a source for antigens. In a direct
comparison, irradiated, apoptotic tumor cells appear to be
a superior source for antigen compared to tumor lysates for
DC-mediated T cell stimulation [137]. Indeed, stimulation
of T cells from the peripheral blood or bone marrow with
autologous dendritic cells that had been coincubated with
puriﬁed, irradiated myeloma cells may give rise to T cell lines
with speciﬁc IFN-γ production and lytic activity of primary
autologous tumor cells. In this approach, presentation of
antigens from myeloma cell lines by DC s is greatly enhanced
by coating of myeloma cells with a speciﬁc antibody such
as anti-CD138 [138]. Similar results with induction of
speciﬁc, cytotoxic T cell activity against autologous myeloma
cells have also been reported when DCs were loaded with
myeloma cells lysed by repetitive freeze-thaw cycles [139].
Among the leukemia-associated antigens (LAAs),
RHAMM, proteinase 3, and WT-1 have been already tested
for clinical peptide vaccination [116, 140]. A Phase I/II R3
peptide vaccination for patients with AML, MDS, and MM
overexpressing RHAMM was initiated [141]. Patients with a
diagnosis of MM were included who fulﬁlled the following
criteria: partial remission (PR) or near-complete remission
(NCR) after a high-dose chemotherapy with melphalan and
ASCT; immunoﬁxation still positive; free light chains in
serum and/or urine were detectable. The patients expressed
both RHAMM and HLA-A2 as assessed by RT-PCR and ﬂow
cytometry. Authors found a signiﬁcant increase of speciﬁc
CD8+ T cells recognizing the RHAMM-R3 peptide in 4/9
patients by ELISpot analysis and/or by tetramer staining.
However, due to the number of patients in this Phase I trial
no meaningful statistical analysis could be performed.
The interaction between the CD40 ligand (CD40L) on
activated T lymphocytes and CD40 on the APCs has been
shown to be crucial for the induction of cytotoxic T lym-
phocyte (CTL) immunity. CD40−B cells can be generated in
large numbers from small amounts of peripheral blood and
have the potential to serve as a cellular adjuvant for im-
munotherapy [142]. The CD40−B cells loaded with tumor
lysates induced strong target-speciﬁc CTLs, based on large
numbers of IFN-γ- secreting cells and higher cytotoxic ac-
tivityagainsttargetcellscomparedtotheCD40−Bcellswith-
out the tumor lysates [142].
Recently, hTERT (human telomerase reverse transcrip-
tase) was detected in the majority of human malignancies.
HTERT can be a target for CT−T lymphocytes in several
malignancies including MM in vitro [143]a n din vivo [144].
Kryukov et al. studied antigen-speciﬁc and HLA-A2-restric-
ted cytotoxic activity against an ARH77 myeloma cell line6 Clinical and Developmental Immunology
in vitro [145], when HLA-A2-speciﬁc hTERT-derived non-
apeptide was used as a TAA. Myeloma-speciﬁc cytotoxic ac-
tivity of hTERT-reactive CTLs was established by repeated
stimulation of the CTLs via DCs loaded with hTERT-derived
nonapeptide.
In cancer immunotherapy, including MM, there is no
proof that a cancer vaccine has to stimulate a large number
of T cells in order to initiate tumor rejection. T cell responses
to tumor antigens may be of a low level, and negative results
obtainedwithmostexvivoassaysmaynotexcludethebeneﬁ-
cial eﬀect of tumor-speciﬁc T cells in vivo. After stimulation,
myeloma-reactive T cells activate and produce IFN-γ.S u c h
activated T cells can be eﬃciently expanded in vitro without
loss of speciﬁcity to the target myeloma antigens. Cytotox-
icity of expanded myeloma-reactive T cells was evaluated
and demonstrated a strong and myeloma-speciﬁc response
which, as expected, was mainly CD8+ CTL dependent [146].
Further expansion of sorted myeloma-reactive T cells con-
taining both helper and cytotoxic T cells does not lead to
loss of antigen speciﬁcity but, rather, leads to potentiation of
cytotoxicity, probably via beneﬁcial cytokine production by
helper T cells that positively inﬂuences further proliferation
and the cytotoxic potentiality of CD8+ CTLs. Immunization
with MUC1 protein results in activation of CT−Tl y m p h o -
cytes both in vitro and in vivo [147]. After immunization
with this antigen, activated T lymphocytes were separated
immunomagnetically and expanded in vitro [148]. Speciﬁc
cytotoxicity of the expanded T lymphocytes was tested
against a myeloma cell line [148]. Such an approach can also
be useful therapeutically as, after enrichment, myeloma-
r e a c t i v eTc e l l sc a nb ee x p a n d e din vitro to reach amounts
useful and eﬀective in clinical trials. An approach which was
recentlyintroducedintotheclinicalsettingreliesonadoptive
transfer of T cells expressing transgenic T cell receptors
(TCRs) with antitumor function; however, there is a critical
bottleneck in identifying high-aﬃnity TCR speciﬁcities nec-
essary for treatment of various malignancies [149].
In general, the process of identiﬁcation and characteriza-
tion of individual myeloma speciﬁc T cell clones can be used
as a tool for immune monitoring during cancer treatment.
Depletion of CD25+ regulatory T cells by speciﬁc mon-
oclonal antibodies like denileukin diftitox (Ontak; [150]) or
addition of toll-like receptor stimulation oligodinucleotides
might pave the road for new approaches in the ﬁeld of pep-
tide vaccination [151]. Moreover, advances are being made
in the combination of peptide vaccination with alloSCT
[140].
7. Vaccines for Myeloma Based on
DendriticCells
Preclinical studies have shown that DCs generated from my-
eloma patients were functional and could eﬃciently present
Id determinants to autologous T cells [83, 152]. DCs pulsed
with Id protein can be used to induce the type-1 anti-Id
response in myeloma patients. Wen and coworkers [79, 95]
reported results from vaccinating an MM patient with auto-
logous Id protein-pulsed DCs generated from blood adher-
ent cells. An immune response against Id was demonstrated
in many of the patients. A minor clinical response (25% re-
duction in the M-component) was observed in one patient
and stable disease in the remaining patients. Cull and co-
workers [153] reported on vaccinating two patients with
advanced refractory MM with Id-pulsed DCs combined
with GM-CSF. An anti-Id T cell proliferative response was
detected in both patients, which was associated with IFN-γ
production by the T cells. One patient also had an anti-Id
humoral response. Subcutaneous DC vaccination indeed in-
duces better antimyeloma responses than intravenous DC
vaccination [154–156].
DC vaccines can also be produced in the form of fusion
of tumor cells with DCs. Vaccination with fusions of tumor
cells and DCs is an eﬀectivetreatmentinanimaltumormod-
els[157].Inamurineplasmacytomamodel,vaccinationwith
DCs fused with mouse 4TOO plasmacytoma cells was as-
sociated with induction of antitumor humoral and CTL re-
sponses [158]. Immunization with the fusion cells protected
mice against tumor challenge and extended the survival of
tumor-established mice without eradication of the tumor
cells. Addition of IL-12 helped eradicate the established
tumor. In a more recent study, human myeloma cells, either
primary myeloma cells from patients or a myeloma cell line
U266, were fused to human DCs [159]. Fusions with mature
rather than immature DCs induced higher levels of T cell
proliferation and activation, as assessed by intracellular
IFN-γ expression, and stronger CTL activity against the tu-
mor cells [160, 161].
Based on these results, a clinical trial was designed to
evaluate the eﬃcacy of vaccinating myeloma patients with a
fusion of myeloma cells and autologous mature DCs [159].
However, patients with MM have DCs that are function-
ally defective [42]. In order to generate potent functional
DCs, alternative methods for blocking some inhibitory
s i g n a l sh a v eb e e nt e s t e d[ 41, 162]. It was reported that the
inhibitory factors and abnormal signaling pathways of DCs
during maturation with tumor antigen might be responsible
for the defective activity of DCs in MM and suggested that
the way to overcome these abnormalities is by neutralizing
the signaling that would lead to suppressing the immune
response [163]. In an attempt to increase DC potency by the
use of cytokine combinations, alpha-type-1-polarized DCs
(αDC1s) that are induced to mature using the αDC1-po-
larizing cytokine cocktail (interleukin (IL)-1β,t u m o rn e c r o -
sisfactor(TNF)-α,interferon(IFN)-α,IFN-γ,andpolyinosi-
nic:polycytidylic acid [poly(I:C)]) can be developed to gen-
erate strong functional CTLs in several diseases, compared
to standard DCs (sDCs) [164]. When mononuclear cells
(MNCs) from the BM are used as a source of tumor an-
tigen, the DCs usually show weak antigenicity due to pos-
sible contamination withnormal cells.To overcomethis pro-
blem, the previous report demonstrated that DCs pulsed
withpuriﬁedandoptimizedmyelomaantigencouldgenerate
potent myeloma-speciﬁc CTLs [165]. Recently, the possibil-
ity of cellular therapy using autologous αDC1 pulsed with
the ultraviolet B (UVB)-irradiated allogeneic myeloma cell
line, ARH77 with HLA-A0201+, which could generate my-
e l o m a - s p e c i ﬁ cC T L sa g a i n s ta u t o l o g o u sm y e l o m ac e l l sw a s
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Vaccination with DC/tumor fusions induces antitumor
immunity in the majority of the patients; however, the re-
sponses are transient and not always associated with clinical
beneﬁt. One potential limiting factor is the regulatory T
cells. Developing strategies that promote the expansion of
functionally competent tumor reactive T cells and limit the
inﬂuence of regulatory T cells is necessary to improve the
eﬃcacy of the DC/MM fusion vaccine. One approach is
vaccination in conjunction with ASCT which facilitates vac-
cine response by inducing a minimal residual disease state
and limiting the inhibitory inﬂuence of the myeloma cells.
In preclinical models, stem cell transplantation results in the
in vivo depletion of regulatory T cells, transient loss of tumor
mediated tolerance, and enhanced capacity to respond to
tumor vaccines [167, 168].
PD-1 expression is upregulated on T cells isolated from
patients with MM, and PD-1 blockade is associated with
enhancement of T cell response to the vaccine. Luptakova
et al. examined the eﬀect of lenalidomide on T cell activa-
tion and polarization, PD-1 signaling, and vaccine-induced
responses in vitro [169]. In vitro exposure to lenalidomide
results in enhanced T cell activation in response to direct
ligation of the costimulatory complex and stimulation by the
DC/myeloma fusion vaccine, suppressed T cell expression
of PD-1 and regulatory T cells, 2 critical pathways respon-
sible for tumor-mediated immune suppression. This is the
ﬁrst demonstration of an interaction between lenalidomide
and the PD-1/PDL-1 pathway. These ﬁndings support the
developmentofcellularimmunotherapyinconjunctionwith
lenalidomide, including its use with the DC/myeloma fusion
vaccine[169].LenalidomideresultedingreaterdegreeofTh1
polarization as manifested by a 2-fold increase in the per-
centage of CD8+ T cells expressing IFN-γ (P = 0.02) and a
decrease in the percentage of regulatory T cells from 6.88%
to 3.13% (P = 0.02). In addition, the percentage of NK cells
expressing IFN-γ was 5-fold greater (P = 0.03) in the pre-
sence of lenalidomide.
Lastly, Luptakova et al. found that vaccination with
fusion-mediated stimulation of autologous T cells in the pre-
sence of lenalidomide resulted in an increase in the percen-
tage CD4+ and CD8+ T cells expressing IFN-γ (5.35% to
8.79%, P = 0.06, and 6.37% to 9.85%, P = 0.03, resp.). The
proportion of regulatory T cells decreased from 9.57% to
4.43% in the presence of lenalidomide (P<0.01). As with
nonspeciﬁc stimulation, PD-1 expression on CD4+ cells in
the presence of lenalidomide decreased from 24% to 19%. In
concert with these ﬁndings, exposure to lenalidomide re-
sulted in increased cytotoxic T lymphocyte-mediated lysis of
autologous tumor targets (from 25% to 36%). At this time
several clinical studies recruit patients for clinical investi-
gation [169].
8. NK Cells




production of cytokine, costimulatory molecules expression,
and T cell stimulation, resulting in a more eﬃcient Th1-type
polarization and CTL generation [172, 173]. Nguyen-Pham
et al. investigated the possibility of generating potent DCs
throughstimulationwithNKcellsinthepresenceofdiﬀerent
cytokines in order to induce myeloma-speciﬁc CTLs against
MM in vitro [174]. They demonstrated that potent DCs can
be generated by stimulation with NK cells, as activator help-
er cells, in the presence of TLR3 agonists, IFN-γ, and IL-2.
NK cell-stimulated DCs exhibited high expression of costim-
ulatory molecules and high production of IL-12p70 [174].
These DCs induce high potency of Th1 polarization and
exhibit a high ability to generate myeloma-speciﬁc CTL re-
sponses. These results suggest that functionally potent DCs
can be generated by stimulation with NK cells and may
provide an eﬀective source of DC-based immunotherapy in
multiple myeloma [174].
Recently, it has been shown that autologous NK cells
from myeloma patients expanded ex vivo with IL-2 displayed
signiﬁcant cytotoxic activity against primary autologous
plasmacells[38].However,exvivoorinvivoexpansionofthe
NK cells with IL-2 carries a dose-limiting toxicity.
The potential of tumor-activated (TaNK) cells to induce
lysis has been explored [175]. Recent study was designed to
assess the relative function in vitro of NK and TaNK cells
from MM patients compared to normal healthy controls in
thelysisoftumorcelllinesandfreshlyisolatedprimaryauto-
logous and allogeneic MM cells [175]. In this study, the au-
thors demonstrated that TaNKs from myeloma patients can
induce a substantial lysis of myeloma cell lines as well as au-
tologous and allogeneic freshly isolated BM malignant plas-
ma cells. This was in accordance with the degree of killing
reported in the study by Alici et al. [38], where NK cells
underwent ex vivo expansion with the addition of IL-2. This
potential is not aﬀected either by the disease status or
by the antimyeloma treatment, including novel agents and
dexamethasone. These ﬁndings provide information for
the use of TaNK cells in MM therapy and particularly in
combination with the novel agents.
Modulation of inhibitory and activating NK receptor
ligands on tumor cells represents a promising therapeutic
approach against cancer, including MM. Proteasome in-
hibitors, in particular lactacystin, that most probably target
inhibitory KIR ligand class I on the MM tumor cells may
contribute to the activation of cytolytic eﬀector NK cells in
vitro, enhancing their antimyeloma activity [176].
Several reports showed a reciprocal relationship between
NK and Tregs [177]. In addition Tregs could suppress the
function of NK cells [178]. A unique mouse model of MM,
namely, 5T2MM-bearing mouse, was useful for elucidating
the pathophysiological mechanisms underlying the disease
[179]. Depletion of Tregs, a proposed strategy in cancer
immunotherapy, was tested using cyclophosphamide (CY).
Low-dose CY, which selectively depletes Tregs, decreased
MM incidence, in contrast to high-dose CY, which was
generally cytotoxic, and did not reduce MM incidence. On
theotherhand,thenumberandfunctionofNKcellscouldbe
recovered, the production of IFN-γ was enhanced, and DCs
could continue their diﬀerentiation and become mature and
ready for activation [179].8 Clinical and Developmental Immunology
Th1-typecytokinesinvariantnaturalkillerT(iNKT)cells
have been shown important in initiating antitumor immune
responses. Through the production of IFN-γ, iNKT cells can
stimulate the activation of downstream eﬀectors including T
cells, NK cells, dendritic cells, and macrophages and increase
NK and T cell proliferation and cytotoxicity through IL-2
production [180–183]. However, both quantitative and qua-
litative defects of iNKT cells in advanced MM hamper their
antitumoreﬀects.Songetal.developedanovelimmunother-
apeutic strategy directed at the activation and expansion of
Th1-polarized iNKT cells from MM patients [184]. Func-
tional iNKT cell lines were generated from MM patients with
a-GalCer-pulsedDCsandfurtherimprovedbylenalidomide.
These results provide the preclinical feasibility and rationale
for iNKT cell-mediated immunotherapy in MM [184].
9. Monoclonal Antibodiesin
the Treatment of MM
9.1. General Considerations. A wide range of antigens may
ultimately be targeted in MM therapy, including those in-
volved in cell survival, antiapoptotic pathways, cell-to-cell
communication, angiogenesis, and interactions between
MM cells and bone marrow stromal cells (BMSCs) and/or
other cells in the BM microenvironment [26, 185]. These
potential targets include signalling molecules, cell surface
receptors and other cell surface proteins, plasma cell growth
factors, and mediators for adhesion. Ideally, a useful target
for mAb-based MM therapy should be expressed exclusively
on the majority of the MM cells (or other target cells such as
those involved in angiogenesis) [26]. The clinical eﬃciency
of most therapeutic antibodies is based on their capacity
to recruit and activate cytotoxic eﬀector mechanisms of the
innate immune system. This occurs either by engagement of
activatingFcreceptorsexpressedonNKcellsormacrophages




receptors) and the use of mAbs as targeted “carriers” of
cytotoxic agents [4].
CD20. Clinical studies of rituximab therapy for MM have
beendisappointing,asonlyafewofthepatientsshowedmin-
imalresponse[186].Thefailureofrituximabinthissettingis
potentially attributable to the small number of MM patients
(estimated at 13–22%) who express CD20 in primarily a low
proportion of plasma cells. Another mechanism that may
render MM refractory to rituximab is the possibility that
MM cells express increased levels of complement-inhibiting
proteins,thusreducingtheeﬀectivenessofCDC.Inaddition,
Fc-c receptor polymorphism may limit the eﬀectiveness of
ADCC as a killing mechanism. Finally, the use of rituximab
for MM may induce a selective loss of the CD20 expression
[186]. Although it is conceivable that rituximab may be
useful for some carefully-selectedMM patients, such as t (11;
14) translocation patients, who exhibit relatively high CD20
expression [187], it is unlikely to be of value for the majority
of cases.
CD40. CD40 is a transmembrane protein belonging to the
TNF-α superfamily, normally expressed in the resting cell
types, with the highest levels of expression found in B and
DCs [188–190]. CD40 is expressed at high levels on the
surface of MM cell lines and primary MM cells [191]. The
binding of CD40 to its natural ligand determines its func-
tional activation that, in turn, induces diverse biologic events
including MM-cell proliferation and migration via the
PI3K/AKT/-NFκBsignalingpathway.CD40isalsoexpressed
byBMSCs,anduponactivationittriggersthesecretionofIL-
6 and VEGF [192–194]. Thus, inhibition of CD40−CD40L
interaction could exert antimyeloma activity through the
b l o c k a g eo fs e v e r a lc r i t i c a lp a t h w a y si nM Mo ri nB M S C s .
Monoclonal antibodies developed against CD40 (SGN-40,
CHIR-12.12) [195]h a v es h o w nam o d e s tc y t o t o x i ca c t i v i t y
against MM cell lines and primary MM cells when used as
single agents for treatment [196]. The mechanisms of action
rely on the inhibition of CD40−CD40L interaction and ac-
tivation as well as on ADCC [197, 198]. Although earlier
trials in NHL and MM were promising, a Phase II NHL tri-
al comparing therapy with the anti-CD40 antibody SGN-40
withexisting treatmentsalone wasstopped because of lack of
eﬃcacy. Horton et al. described the characterization of
XmAbCD40, a humanized anti-CD40 antibody with in-
creased FcγR binding that facilitates highly enhanced ADCC
against B-lymphoma, leukemia, and MM cell lines and
against primary tumor cells from patients with CLL and
plasma cell leukemia (PCL) [199]. XmAbCD40 shows nearly
2 orders of magnitude increased binding to FcγRIIIa and 1
order of magnitude increased binding to FcγRIIa. The in-
creased aﬃnity for FcγRIIIa translated into dramatically
increased NK cell-mediated ADCC. Results were consistent
in several cell lines expressing diﬀerent levels of CD40 an-
t i g e na sw e l la si np a t i e n t - d e r i v e dp r i m a r yt u m o r s[ 199].
The observation that SGN-40-induced MM cell death is
enhanced by lenalidomide [200] led to its evaluation in a
Phase I study in combination with lenalidomide and dexa-
methasone in patients with relapsed or refractory MM; an
overall response (OR) of 39% (13/36) was seen, with some
activity noted in patients receiving prior lenalidomide [201].
Phase I clinical trials of SGN-40 in combination with other
agents are currently ongoing [202].
Lucatumumab is a fully human anti-CD40 MAb that
inhibits MM cell growth in vitro, even when MM cells are
cocultured with BMSCs. Animal studies have shown that
the primary cytotoxic mechanism is ADCC [198]. However,
a Phase I study of lucatumumab in patients with relapsed/
refractoryMMwasterminatedbecauseofminimalbiological
and clinical activity (NCT00231166).
CS1 (CD2 Subset 1, CRACC, SLAMF7, CD319, or 19A24).
CS1 is a cell surface glycoprotein of the immunoglobulin-
gene superfamily with high expression on the surface of MM
cell lines and on plasma cells from MM patients [203]. It
is not expressed on other normal tissues [203]. The role of
CS1 is not well understood; however, there is evidence that it
participates in promoting and supporting MM cell adhesion,
tumor growth, and proliferation through interactions withClinical and Developmental Immunology 9
bone marrow stromal cells mediated by c-maf pathway ac-
tivation [203, 204].
A humanized mAb developed against CS1 elotuzumab
(HuLuc63) has been proven to induce signiﬁcant antimye-
loma activity both in vitro and in vivo [203, 205]. In vitro,
the employment of bortezomib has been shown to increase
HuLuc63-induced ADCC [206]. In vivo injection of the mAb
signiﬁcantlyinducedtumorregressioninxenograftmyeloma
mouse models [203]. Based on these results, Phase I clinical
trials are underway to evaluate the safety and toxicity of
the HuLuc63 in myeloma patients [207]. Elotuzumab de-
monstrated acceptable toxicity but its antitumor activity was
only modest: no responses were seen, although elotuzumab
did induce stable disease (SD) in six of 19 patients [208].
Clinical studies of elotuzumab combined with either lena-
lidomide plus dexamethasone or with bortezomib were
therefore initiated and are showing considerable promise. In
a preliminary analysis of an ongoing phase I study of elo-
tuzumab plus bortezomib, the ORR (partial pesponse (PR)
or better) was 48% for 27 evaluable patients, and responses
were achieved for several bortezomib-refractory patients. A
clinical response was seen in 17/27 (63%) patients. The re-
sponse rate was lower among heavily pretreated patients (>3
prior therapies) and the median time to progression was
9–46 months [209]. In a preliminary analysis of an on-
going Phase Ib combination study with lenalidomide and
dexamethasone, the ORR was 82% for all treated patients
(n = 28), 96% for lenalidomide-na¨ ıve patients (n = 22), and
82% among patients who had been refractory to their most
recent treatment (n = 11) [210]. In a Phase II study of the
same combination, the ORR was 85% for evaluable patients
(22/26), and the remaining four patients had SD; 31% achie-
ved either a complete remission (CR) or very good partial
response (VGPR) [211]. Elotuzumab is therefore the ﬁrst
mAbincombinationwitheitherbortezomiborlenalidomide
and dexamethasone to demonstrate clinically meaningful ef-
ﬁcacy in relapsed/refractory MM.
CD138 (syndecan-1). syndecan-1 is a member of the synde-
can family, which includes cell-surface heparan sulfate pro-
teoglycans involved in cell adhesion, maturation, and pro-
liferation [212]. The high levels of heparan sulfate in the
tumor microenvironment resulting from syndecan-1 shed-
ding also act as positive regulators that condition the micro-
environment for robust tumor growth. This antigen is usu-
allyabsentonhaematopoieticcells;converselyitisfrequently
expressed on normal and myeloma plasma cells. When
present at high levels in the serum, syndecan-1 is an in-
dependent indicator of poor prognosis [213–215]. Studies in
animal models have shown that high levels of soluble syn-
decan-1 enhance both the growth and metastasis of tumors
[216]. Syndecan-1 has been explored as a candidate antigen
for antibody targeting of toxins to the tumor cell surface
[138, 217–219].
CD74. CD74 expression has been demonstrated for more
than 90% of B-cell malignancies [220]a n df o rah i g hp e r -
centage of MM cases (around 80%). To assess CD74 as a
therapeutic target, an anti-CD74 mAb, LL1, has been de-
veloped [221]. LL1 activity hardly relied on ADCC and CDC
mechanisms. This feature makes it feasible to use drug- and
toxin-conjugated or radiolabelled forms of LL1 instead of
unconjugated ones. hLL1-dox (IMMU-110), for example, is
an immunoconjugate composed of doxorubicin conjugated
to hLL1 IMMU-110 which has been evaluated in preclinical
studies with non-Hodgkin’s lymphomas and MM models,
resulting in the achievement of an excellent therapeutic re-
sponse [221, 222]. IMMU-110 appeared to be safe in a
monkey model of MM [222]. IMMU-110 is being evaluated
in a Phase 1/2 study (NCT00421525), and a Phase 2 study is
currently ongoing (NCT01101594).
CD162. CD162 has been found to be constitutively ex-
pressed in indolent and aggressive plasma cell disorders, in-
cluding MM, and in normal plasma cells [223]. The anti-
CD162 blocking mAb KPL1 has been recently tested in vitro.
KPL1-mediated CD162 crosslinking was proven to induce
death MM cells, in MM cell lines and in neoplastic cells puri-
ﬁed from patients, mainly by activating the mitochondrial
pathway of apoptosis [224]. KPL1 also mediated a signiﬁcant
induction of ADCC and to a lesser extent complement-
dependent cell lysis. Its action could be strongly enhanced
by adding blocking mAbs against the complement regulatory
proteins CD46, CD55, and CD59 highly expressed on the
surface of MM cells [224].
CD66. CD66 proteins are expressed in a number of iso-
forms, which have a wide range of biologically important
functions including cell adhesion, cellular migration, patho-
gen binding, and activation of signalling pathways. This was
utilized in recent Phase I and II clinical trials [225, 226]
for targeted delivery of radiotherapy to the BM as a part of
the conditioning regimen for transplantation in acute leuk-
emias and MM. The expression of CD66a but no other
CD66 isoforms on two human myeloma cell lines (U266 and
ARH77) and on plasma cells from patients with MM [227]
may help in the optimization of future radioimmunother-
apeutic strategies by supporting the use of a monoclonal
CD66a antibody for targeted radiotherapy in patients with
MM [227].
Beta2-Microglobulin (β2M). β2M is a nonglycosylated poly-
peptide, which is a part of the MHC class I molecule on the
surface of nucleated cells [228]. β2M is normally found in
body ﬂuids, but elevated serum levels are present in hema-
tological malignancies [229], including MM [230], and cor-
relate with a poor prognosis. The mAbs against β2M have a
remarkably strong apoptotic eﬀect on myeloma cells [231].
The anti-MM activity of this antibody was conﬁrmed by
in vivo in a MM xenograft mouse model experiment which
demonstrated selective eﬀect on tumor cells without dam-
aging BM hematopoietic cells of implanted human bone
or murine organs expressing β2M/HLA-A2 molecules [231,
232]. Therefore, such mAbs oﬀer the potential for a thera-
peutic approach to hematological malignancies [233].
CD38. Under normal conditions, CD38 is expressed at rel-
atively low levels on lymphoid and myeloid cells and in some10 Clinical and Developmental Immunology
tissuesofnon-hematopoieticorigin[234].Inthepast,several
Abs to human CD38 have been generated. These Abs induce
killingofneoplasticBcelllines[235,236].Therelativelyhigh
expression of CD38 on all malignant cells in MM [237, 238]
in combination with its role in cell signaling suggests CD38
as a potential therapeutic Ab target for the treatment of MM.
Two CD38 mAbs are currently in clinical development: a hu-
manized mAb (SAR650984) and a human mAb (daratumu-
mab) [239]. Daratumumab was found to eﬀectively kill MM
tumor cells by ADCC and CDC. It was active at low con-
centrations in a SCID mouse xenograft tumor model. Dara-
tumumab is currently in a Phase I/II safety and dose ﬁnding
study for the treatment of MM (NCT00574288). Results of
this preliminary study are awaited with interest, with early
reports suggesting favourable tolerability and disease stabi-
lization for some patients [28]. In a series of experiments
using a CD38+ MM cell line, puriﬁed MM cells, and full
BM mononuclear cells (BM-MNC) of MM patients contain-
ing 2–50% malignant plasma cells, van der Veer et al. de-
monstrated that lenalidomide signiﬁcantly improves dara-
tumumab-dependent lysis of MM cells [240].
PD1. Accumulating experimental evidence indicates that
PD1 is a coinhibitor and primarily involved in the regulation
of T cell and NK-cell responses. Anticancer immunotherapy
based on antibodies directed against the B7 family of recep-
tors, particularly the B7 homologue 1 (B7-H1)-programmed
death 1 (PD1) system, suggests a promising novel approach
for promoting immune responses against cancer as well as
breaking up tumor resistance and dormancy. CT-011 is a
humanized IgG1 mAb that modulates the immune response.
Interaction of CT-011 with PD-1 leads to stimulation of the
NK-cellactivityandtoextendedsurvivalofeﬀector/memory
T cells, culminating in the enhancement of antitumor im-
mune response and the generation of tumor-speciﬁc mem-
ory cells [241]. CT-011 was recently administered to patients
with various hematologic malignancies, including MM at an
advanced stage of their disease and following chemotherapy
and/or stem cell transplantation [242]. Clinical beneﬁt was
observed for 33% of the patients with one CR [242].
Currentlyanewclinicalstudyrecruitspatientstoevaluatethe
eﬃcacy and safety of CT-011 following autologous trans-
plantation and a Phase II study to determine if cellular
immunity is induced by treatment with CT-011 and DC/my-
eloma fusion cells in conjunction with stem cell transplanta-
tion (NCT01067287).
IL-6. IL-6 has been recognized as a key cytokine in the
development and progression of MM, exerting antiapoptotic
activity and multiple additional eﬀects within the BM. IL-6
is produced predominantly by BMSCs and is upregulated by
multiple cytokines [185]. Both IL-6 and its receptor, IL-6R,
are potential targets for mAb-based intervention. A chim-
sericanti-IL-6mAb,siltuximab(CNTO328),enhancesdexa-
methasone-induced cytotoxicity in MM cell lines, and in
MMcellsfrompatientsrefractorytodexamethasonetherapy,
italsoenhancesthecytotoxicityofthebortezomibplusdexa-
methasone combination [243]. Siltuximab is currently being
evaluated in MM in multiple single-arm and randomized
Phase II studies, either alone or in combination with bor-
tezomib (NCT01219010, NCT00402181, NCT00911859,
NCT00412321, NCT00401843). Preliminary results in com-
bination with bortezomib have shown promise, with a 57%
objective response rate (ORR), although grade 3+ haemato-
logical toxicities were somewhat common [244]. A Phase III
study of siltuximab or placebo in combination with borte-
zomib and dexamethasone is underway (NCT01266811).
A murine anti-IL-6 mAb, BE-8, has been evaluated in
combination with dexamethasone and high-dose melphalan
as a conditioning regimen for ASCT. The combination in-
duced a response in 13 of 16 patients (81%) and a CR in 6
patients (37.5%). The overall response (OR) was similar to
historical controls by the same group of high-dose melpha-
lan; however, the CR rate appeared to be higher and was
correlated with IL-6 neutralization [245]. In a subsequent
prospective,multicentrerandomizedtrialbythesamegroup,
the addition of BE-8 to the melphalan plus dexamethasone
conditioning regimen showed no improvement in response
or survival rates for patients with high-risk MM [246].
Tocilizumab is a humanized anti-IL-6 mAb currently
approved for rheumatoid arthritis in several countries, and
fortheCastlemandiseaseinJapan,hasdemonstratedeﬃcacy
in a murine MM model [247] and is currently being eva-
luated clinically in MM. Another anti-IL-6 mAb, 1339, has
demonstrated activity on MM cell lines (cocultured with
BMSCs) in vitro and in murine xenograft MM models; it is
not yet being evaluated clinically [248].
VEGF. VEGFisakeycytokinethatpromotesangiogenesisin
a variety of tumour types. Bevacizumab, a humanized anti-
VEGF mAb, is currently indicated for treatment of colorec-
tal cancer. In a Phase II study in patients with relapsed/re-
fractory MM, seven out of 10 patients responded partial res-
ponse (PR) to bevacizumab in combination with low-dose
dexamethasone andlenalidomide [249].Anadditional phase
II study of the same combination reported similar results in
a larger patient population (OR 19/27, 70%) [250], noting
that this response rate was not signiﬁcantly diﬀerent from
that seen in the pivotal Phase III trial of lenalido-
mide plus dexamethasone (61%) [251]. An additional
Phase II study of this combination is currently recruit-
ing patients (NCT00410605), and the drug is also being
evaluated in combination with bortezomib (NCT00464178,
NCT00473590).
GM-2. GM-2 is a ganglioside expressed on MM cells. A
humanized anti-GM-2 mAb, BIW-8962, has demonstrated
in vitro killing of MM cell lines and in vivo eﬀectiveness in
mouse xenograft models, with ADCC and CDC the most
prominent cytotoxic mechanisms [252]. BIW-8962 is being
evaluated as monotherapy in a Phase I/II study for patients
with relapsed/refractory MM (NCT00775502).
CD200. CD200 is a highly conserved transmembrane gly-
coprotein expressed on a wide range of cell types; however,
expression of the receptor for CD200 (CD200R1) is appar-
ently limited to APC of myeloid lineage and certain T cellClinical and Developmental Immunology 11
populations and is thought to deliver inhibitory signals. The
expression of the CD200 gene by MM cells has been found to
be a predictor of poor prognosis in patients with MM [253].
ALXN6000isahumanizedanti-CD200mAbthatiscurrently
being evaluated in a Phase 1/2 study in patients with MM or
B-cellCLL(NCT00648739),withresultsexpectedinthenear
future.
Killer Cell Immunoglobulin-Like Receptors (KIRs). KIRs are
receptors expressed on natural killer (NK) cells and a sub-
set of T cells and function as key regulators of NK cell activi-
ty [254]. IPH 2101 (anti-KIR) is a fully human monoclon-
al antibody blocking interaction between KIR inhibitory
receptors on NK cells with their ligands. By blocking
these receptors, it facilitates activation of NK cells and,
potentially, destruction of tumor cells by the latter. Several
studies are currently underway in smoldering and ﬁrst-
relapse MM (NCT01222286, NCT01217203, NCT00999830,
NCT01248455) and safety and tolerability results are ex-




The immune system of MM patients is impaired by the dis-
ease or by cancer treatments. Along with eﬀorts to develop
functional antibodies, substantial eﬀorts are underway to
develop therapies using antibodies conjugated with potent
cytotoxicagents.Avarietyofhighlycytotoxiccompoundsare
being evaluated for antibody-based delivery, including cali-
cheamicin, doxorubicin, taxanes, maytansinoids, dolas-
tatins, and CC-1065 analogs [255–258]. Immunoconjugate
IMGN901 (BB-10901; huN901-DM1) is composed of a hu-
manized monoclonal antibody that binds with high aﬃnity
to CD56 conjugated with the cytotoxic maytansinoid DM1
through a disulﬁde linkage [258]. Upon binding to a target
tumor cell, the antibody-maytansinoid conjugate is internal-
ized by natural processes, where the conjugate is metabolized
and active maytansinoid metabolites are released [259].
Withinthehematopoieticcompartment,whileCD56expres-
sion is normally restricted to NK cells and a subset of T ly-
mphocytes[260,261]andisabsentfromnormalplasmacells
[262], it is strongly expressed on MM cells in the majority
of MM patients [263–266]. Tassone et al. demonstrated the
activity of IMGN901 against CD56+ MM cells both in vitro
and in vivo. Target-dependent cytotoxicity was shown in
cocultures of CD56+ and CD56− cells [263]. Treatment
with IMGN901 in a human MM tumor xenograft model in
immunocompromised mice showed that the immunoconju-
gatewaseﬀectiveinbothaminimalandbulkydiseasesetting.
The clinical evaluation of IMGN901 was initiated with a
Phase I study in patients with relapsed or relapsed/refractory
MM who failed at least one prior therapy and have CD56+
MM (NCT00346255) [258]. Additive to synergistic activity
has been observed in combinations of IMGN901 with len-
alidomide, bortezomib, or melphalan in MM xenograft
models [267, 268].
BT062 is a chimeric mAb conjugated to maytansinoid
derivativesthatdemonstratesinvitrocytotoxicityandinhibi-
tion of MM cells in mouse xenograft models, apparently via
apoptotic mechanisms; BT062 also inhibits the adherence
of MM cells to BMSCs and abrogates the protective eﬀects
e x e r t e db yg r o w t hf a c t o r sa n dB M S C so nM Mc e l l s[ 269].
Thelocalreleaseofpotentmaytansinoidmoietiesfromtarget
cells and uptake into nearby nontarget cells is the proposed
mechanismforthisactivity[269]andmayhaveanimportant
impact on BT062 eﬃcacy through eradication of tumor cells
that heterogeneously express CD138 or disruption of the
tumor microenvironment by elimination of tumor stromal
cells. A Phase I dose ﬁnding study of BT062 for patients with
relapsed/refractory MM is underway (NCT00723359), and
an additional Phase I/IIa study is ongoing but not recruiting




The BM microenvironment encompasses a wide spectrum of
cell types and extracellular matrix proteins, including ﬁbro-
nectin, collagen, laminin, and osteopontin. Multistep genetic
and microenvironmental changes lead to the transformation
of plasma cells into a malignant neoplasm. Genetic abnor-
malities alter the expression of adhesion molecules on my-
eloma cells, as well as responses to growth stimuli in the mi-
croenvironment [270].
A cardinal clinical feature of MM is the presence of os-
teolytic bone lesions. Myeloma cells disrupt the delicate ba-
lance between bone formation and bone resorption [271,
272]. The inhibition of the Wnt pathway suppresses osteo-
blasts, whereas the ampliﬁcation of the RANK pathway and
the action of macrophage inﬂammatory protein 1 α (MIP1α)
activate osteoclasts [271]. The induction of proangiogenic
molecules (e.g., VEGF) enhances the microvascular density
of bone marrow and accounts for the abnormal structure of
myeloma tumor vessels [273]. Various clinical observations
[274] and experimental studies [275, 276] have linked the
level of the MM bone disease with the disease burden. Tu-
mor cells and stromal cells interact via adhesion molecules
and cytokine networks to simultaneously promote tumor
cell survival, drug resistance, angiogenesis, and disordered
bone metabolism. In addition, the amounts of several of
immunologically active compounds increase including TGF-
b, IL-10, IL-6, VEGF, Fas ligand, MUC-1, cyclooxygenase
(COX)-2, and related prostanoids and metalloproteinases
[277].
In addition to therapy directed at MM cells and tumour
promoting interactions, some eﬀorts have been devoted to
mAb therapy directed against the development of end-organ
complications; to date, these eﬀorts have been restricted to
the suppression of myeloma-related bone disease.
Angiogenesis is considered a hallmark of MM progres-
sion. As indicated before in patients aﬀected by MM sy-
ndecan-1, a heparan sulphate proteoglycan is overexpressed
by myeloma cells in the BM and peripheral blood [212].12 Clinical and Developmental Immunology
The high levels of heparan sulfate in the tumor microen-
vironment resulting from syndecan-1 shedding also act as
positive regulators that condition the microenvironment for
robust tumor growth. For example, heparan sulfate binds to
and promotes the activity of important angiogenic growth
factors such as ﬁbroblast growth factor-2 (FGF-2) and VEGF
[278, 279]. Recent research has shown that syndecan-1 could
alsobeinvolvedinthemodulationofthegrowthandsurvival
of endothelial cells (ECs) within the BM microenvironment
[280]. Enzymatic remodeling of heparan sulfate proteogly-
can structure and function within the tumor microenviron-
ment is emerging as an important mechanism for dynamic
regulation of tumor growth [281]. There are three forms of
enzymatic remodeling of heparan sulfate proteoglycans that
are known to occur in myeloma, and other tumors, sulfa-
tases, sheddases, and heparanase, which are active within the
tumor microenvironment, point out the importance of re-
gulated remodeling of heparan sulfate proteoglycans [216,
281–284]. Certain heparinase gene SNPs may contribute to
basalheparanase gene expression. Alterations in this gene are
an important determinant in the pathogenesis of ALL, AML,
andMM[285].Dynamicregulationofheparansulfatestruc-
ture by sulfate 6-O-endosulfatases (Sulfs) present within the
tumor microenvironment can have a dramatic impact on the
growth and progression of malignant cells in vivo [283].
The high serum level of shed syndecan-1 has been asso-
ciated with an unfavourable prognosis [213, 215].
Hence, the designing of novel agents that regulate the re-
modeling processes of heparan sulfate proteoglycans or in-
hibiting of VEGF as discussed previously represents a new
opportunityfortherapeuticcontrolofmalignantcellgrowth.
Huang and zhan investigated the eﬀect of VEGF antisense
(AS) RNA on proliferation and apoptosis in myeloma cell
line U266 as well as on angiogenesis in endothelial cell
ECV304 and to explore the feasibility of gene therapy for
MM using VEGF antisense RNA [286]. VEGF121 cDNA was
inserted into a multiple clone site of eukaryotic expression
vector pIRES2-EGFP to construct the recombinant plasmid
AS-VEGF. The recombinant plasmid was transfected into a
human myeloma cell line U266. Expression of VEGF mRNA
and protein decreased more signiﬁcantly in U266 cells trans-
fected by AS-VEGF than that in control group. VEGF anti-
sense RNA can inhibit the expression of VEGF gene in
U266 cells, thereby inhibits the proliferation of U266 cells,
increases the apoptosis of U266 cells, and inhibits angiogen-
esis in vitro [286].
Another novel therapeutic concept related to the micro-
environment is the introduction of antiadhesion strategies.
Podaretal.evaluatedthetherapeuticpotentialofthenew-in-
class molecule-selective adhesion molecule (SAM) inhibitor
Natalizumab, a recombinant humanized IgG4 monoclonal
antibody, which binds integrin-α4, in MM [287]. Natalizu-
mab, but not a control antibody, inhibited adhesion of MM
cells to non cellular and cellular components of the microen-
vironment as well as disrupted the binding of already adher-
ent MM cells. Moreover, natalizumab also blocked VEGF-
and insulin-like growth factor 1 (IGF-1)-induced signalling
sequelae triggering MM cell migration. Natalizumab not
only blocked tumour cell adhesion but also chemosensitized
MMcellstobortezomib,inan invitrotherapeuticallyrepres-
entative human MM-stroma cell coculture system model.
Some MM cells that harbor oncogenic translocations re-
main dependent on the stroma for their survival, while oth-
ers acquire additional mutations which aﬀect NF-κB path-
ways and remove their reliance on the bone marrow micro-
environment [288]. Mutations aﬀecting the activation of
NF-κB-inducing kinase (NIK) have been identiﬁed in MM
samples and cell lines, suggesting that NIK could be an im-
portant target for therapy of MM. The majority of MM
samples display high constitutive NF-κB activity and up to
20%resultsfrommutationsinNF-κBsignalingcomponents,
including NIK. Inhibition of NIK may be an eﬀective thera-
peutic for some MM cases. There are several new agents un-
der investigation that induce apoptosis of myeloma cells.
Celastrol is a quinone methide triterpene derived from the
medicinal plant Tripterygium wilfordii,a c t sb yN F - κB path-
way, and induces cell cycle arrest at the G1 phase followed
by apoptosis in human myeloma cell line U266 cells [289].
Several studies have showed that miRNAs play important
roles in the regulation of cell proliferation, diﬀerentiation,
and apoptosis [290, 291]. The deregulation of miRNAs ex-
pression contributes to tumorogenesis by modulating onco-
genic and tumor suppressor signaling pathways.
12. Receptor Activator of Nuclear Factor
Kappa-B Ligand(RANKL)
RANKL promotes bone loss in osteoporosis and contributes
to the development of bone lesions in MM. The inhibition
of RANKL may directly impact myeloma cells that express
RANK and have a therapeutic role in the treatment of MM.
The fully human anti-RANKL mAb, denosumab, has de-
monstrated some eﬃcacy in a Phase II study of patients with
plateau-phase or relapsed MM, including suppression of
the bone turnover marker serum C-terminal telopeptide of
type 1 collagen (sCTx) [292]. Denosumab is currently being
compared with zoledronic acid (the standard of care for pre-
vention of bone disease in several cancers) in patients with
advanced cancers or MM in a randomized Phase III trial
(NCT00330759);resultsintheMMcohorthavethusfarbeen
mixed although positive in other cancers; future trials are
planned in MM to better deﬁne its role.
13. Dickkopf-Related Protein1 (DKK1)
The canonical Wnt pathway plays an important role in con-
trolling proliferation, diﬀerentiation, and survival of OBs.
In MM, high serum DKK1 levels were correlated with
focal bone lesions [293]. The DKK1 produced by MM cells
caninhibitthediﬀerentiationofOBprecursorcells[293]and
bone formation in vitro [294] through a DKK1-mediated at-
tenuationofWnt3a-inducedstabilizationof β-catenin[295].
These ﬁndings conﬁrm DKK1 as an important regulator of
bone formation in the bone microenvironment. The broad
expression in myeloma but highly restricted expression in
normal tissues, together with its functional roles as an OB
formation inhibitor and a potential myeloma growth en-
hancer, make DKK1 an ideal and universal target forClinical and Developmental Immunology 13
immunotherapy. DKK1 (peptide)-speciﬁc CTLs can eﬀec-
tively lyse primary myeloma cells in vitro [296]. A fully
human anti-DKK1 mAb, BHQ880, has demonstrated im-
provement in the bone parameters in murine models and
also appears to have direct eﬀects on the MM cell growth,
possibly via interactions with the BMSCs and the IL-6-re-
lated pathways [297, 298]. BHQ880 is being evaluated in
combination with zoledronic acid in a Phase 2 study in pa-
tients with relapsed/refractory MM (NCT00741377), and
studies in early MM (i.e., smoldering MM) are also under-
way.
14. Biphosphonates-Activated
TC ell - Bas edI m m uno t h e rap y
Aminobiphosphonates, such as pamidronate and zoledron-
ate, were originally developed for osteoporosis but are in-
creasingly used for cancer therapy. They have been shown to
activate Vγ9Vδ2 T cells, and the activated cells were func-
tionally characterized in vitro and in vivo [299–302]. In vivo
study, evaluated administration of low-dose IL-2 in combi-
nation with pamidronate to patients with low-grade non-
Hodgkin lymphoma or MM, showed that only patients with
signiﬁcant in vivo proliferation of γδ T cells responded to
treatment [303]. Abe et al. [304] in a clinical phase I study
evaluated the clinical and immunological eﬀects of zole-
dronate-activated Vγ9Vδ2 T lymphocyte-activated killer
(LAK). Six patients with MM received no antimyeloma ther-
apy in the preceding 2 months and during the study period
received four biweekly intravenous infusions of zoledronate-
activated Vγ9Vδ2 T LAK cells generated from the culture
of PBMCs in the presence of zoledronate and IL-2.
This showed that administration of zoledronate-activated
Vγ9Vδ2 T LAK cells, a safe and immunotherapy for MM pa-
tients,ispromising, andzoledronate-activatedVγ9Vδ2Tcel-
ls warrant further clinical investigations.
15. ChangesinMesenchymalStromalCellsfrom
Multiple Myeloma Patients
BM-derived mesenchymal stromal cells (MSCs) are precur-
sors of OBs and diﬀerentiate preferentially into bone-form-
ing cells both in vitro and in vivo. MM cells were suggested
to target MSCs thereby diverting their functions to serve the
MM cells. This idea led to studies of the functions of MSCs
derived from MM patients (MM-derived MSCs) compared
to those of healthy individuals; it was suggested that MSCs
from myeloma patients exhibit defective functions [68–70]:
MM-derived MSCs were reported to exhibit decreased col-
ony-forming unit number [70], growth impairment [70],
reduced osteogenic diﬀerentiation [68], and increased IL-6
secretion [68, 70]. However, these observations were not re-
producible in all reports [68–70]. Some authors focused on
toll-like receptor (TLR) ligands and on the cytokine epider-
mal growth factor (EGF). They [305–310] have shown that
TLRactivationmodulatesMSCproliferation,migration,and
diﬀerentiation. However, MM-derived MSCs exhibited re-
duced activation of extracellular signal-regulated kinases
(ERK1/2) and may therefore represent a general property of
this signaling pathway in MM-derived MSCs. These altered
responses persisted in MSCs from MM patients following
extended culture and passaging in vitro, indicating that these
cells are permanently modiﬁed. Activation of MAPK path-
way contributes to drug resistance, growth, and survival
[311]. MSCs derived from MM patients have been shown to
exhibit diﬀerent gene expression proﬁles when compared to
control MSCs [68, 312]. Furthermore, these MSCs have been
suggested to be genomically altered [313]. MM-derived
MSCs are intrinsically and permanently modiﬁed. The treat-
ment of the disease may therefore require not only the
elimination of the tumor cells but concomitantly treatment
or replacement of stromal elements.
16. Immunotherapy after Autologous Stem Cell
Transplantation for MM
A major area of investigation is to develop strategies to elicit
myeloma-speciﬁc immune responses that will selectively
eliminate malignant cells and eradicate residual disease fol-
lowing ASCT. High-dose melphalan induces severe and per-
sistentimmunosuppressioncharacterizedbyadelayedrecov-
ery of CD4 T cells that remain below normal counts for
months to years after ASCT [314, 315] ,ar e s t r i c t e dTc e l lr e -
pertoire [316], and impaired T cell functions including an
increased susceptibility to apoptosis [317], a reduced prolif-
eration intensity upon stimulation with mitogens or deﬁned
antigens and a default in Th1 cytokine production that lasts
at least one year after ASCT in patients with MM [318, 319].
The B-cell immune response is also altered after ASCT since
levels of plasma antibodies after one recall vaccination are
below those found in healthy donors [315]. T cell functions
are impaired after transplantation in patients with MM de-
s p i t ear e c o v e r yo fn o r m a ln u m b e r so fTl y m p h o c y t e s[ 317–
319]. In theory, the posttransplantation phase should be
highly amenable to the application of immunotherapy be-
cause of a lower tumor burden. However, after high-dose
therapy, the immune system is characterized by immune cell
depletion and impaired function that may last for years
[314]. The therapeutic induction of rapid lymphocyte re-
covery consistents that unmanipulated lymphocyte levels
in patients with myeloma correlate to event-free survival
(EFS) [320–323]. Rapoport et al. have developed a strategy
forinducing an eﬀectiveantitumor immune response during
the posttransplantation period and to control or eliminate
residual disease [324]. The authors hypothesized that en-
hanced numeric and functional recovery of T cells might
provide a platform for posttransplantation tumor vaccine
immunotherapy. The autologous T cells were costimulated
with paramagnetic beads that deliver CD3 and CD28 signals
designed to reverse T cell anergy [325–328]. Patients with
myelomareceivedcostimulatedautologousTcellsafterauto-
transplantation, along with immunizations with a 7-valent
pneumococcal conjugate vaccine (PCV; Prevnar; Wyeth)
[324, 329]. In addition, patients who were positive for hu-
manleukocyteantigenA2(HLA-A2)receivedamultipeptide
tumor antigen vaccine that was based on peptides derived
from human telomerase reverse transcriptase (hTERT) and14 Clinical and Developmental Immunology
survivin, 2 “universal” tumor antigens that are often over-
expressed in myeloma and may have prognostic relevance
[330–332]. In this study adoptive transfer of vaccine-prim-
ed and costimulated autologous T cells generates a rapid
and schedule-dependent recovery of the cellular and hu-
moral immune system in patients with myeloma. Immune
responses to a cancer vaccine occur in a substantial propor-
tion of patients early after autotransplantation [324]. Some
studies have shown high IL-6 plasma levels after ASCT
[333, 334]. Condomines et al. showed that IL-7 and IL-15
plasma levels increase and peak at a median day 8 after HDM
and ASCT in patients with MM [335], supporting results
found in mice by Restifo and coworkers [336]. Increasing
data support the idea that the early period following-ly-
mphodepletion is propitious to promote ampliﬁcation of
adoptively transferred T cells and to enhance their functions.
Several studies in mice and humans showed that homeos-
tatic expansion is associated with faster and more eﬃcient
immune response and that immunization with tumor an-
tigens during lymphopenia generates CD8 T cells with en-
hanced antitumor capacities [337–340]. IL-7, produced by
stromal cells, is required for homeostatic expansion of na¨ ıve
and memory CD4 and CD8 T cells and is critical for their
survival [341]. IL-15 drives antigen-independent homeosta-
tic memory CD8+ αβT cell proliferation [341, 342]. IL-7 and
IL-15 are also required for γδT cell homeostatic expansion
[343]. The γ9δ2T cells exert antimyeloma-speciﬁc cytotoxic-
ity, can be expanded 100-fold with IL-2 and biphosphonate
ex vivo [344], and are present in mobilized autografts [345].
These γ9δ2T cells could be expanded ex vivo and then
grafted after ASCT. CD8 T cells recognizing several myeloma
antigens as MUC-1 [346], cancer-testis antigens [124, 126,
127], or IgG epitopes [347], detected in peripheral blood
of patients, may also be present in HSC harvests. Once
stimulated ex vivo with antigen-pulsed DCs [348], these
antimyeloma cell CD8+ T cellsare ableto kill myeloma cells.
17. Immunotherapy after AllogeneicSCT
Allogeneic transplantation results in long-term disease-free
survival for a subset of patients with MM. The unique ef-
ﬁcacy of allogeneic transplantation is due to the graft-versus-
disease eﬀect that is mediated by alloreactive donor T cells
[5, 349, 350].
Compared with autologous transplantation, allogeneic
transplantation results in lower rates of disease relapse and
higher rates of molecular remission [5, 351–353]. Standard
myeloablative alloSCT for myeloma is associated with a ra-
ther high treatment-related mortality. One approach to re-
duce transplant-related mortality is the use of reduced-in-
tensity conditioning regimens [354] in which the primary
antimyeloma cytoreductive agent is the donor lymphocytes
contained in the graft or administered as part of DLI at a
subsequent time point. The CR rate of allogeneic stem cell
transplantation after standard myeloablative and dose-re-
duced conditioning ranged between 27% and 81% [354–
358]. The ability of donor lymphocyte infusions (DLIs) to
eradicate posttransplant disease relapse demonstrates the
potency of the graft-versus-myeloma eﬀect [37]. Because
only those patients who achieved molecular remission have a
high probability of long-term freedom from disease and cure
[359], a higher number of CRs, especially molecular CRs,
must be reached. For upgrading non-CR into CR may be
used DLI as adoptive immunotherapy after allogeneic stem
celltransplantation.InmostreportsonDLIinmyeloma,DLI
was given for relapse [360–362] and only a few reported on
prophylactic DLI [363, 364]. Most studies till date have used
relatively high T cell doses, resulting in a high rate of aGvHD
up to 55%. DLI given after reduced-intensity conditioning in
a dose-escalating manner resulted in less acute and chronic
GVHD[363].Ayuketal.thusconsidereditimportanttoﬁnd
DLI doses that may induce a graft-versus-myeloma eﬀect
without GvHD [362]. Their data show that it is possible to
achieve remission in myeloma patients who have relapsed,
persistent, or progressive disease following RIC allografting
with much lower T cell numbers with relatively low starting
doses (1.0 106 CD3+/ k gB Wf o ru n r e l a t e dg r a f t sa n d4 . 71 0 6
CD3+/kg BW for sibling grafts). The incidence and severity
ofaGvHDandcGvHDwererelativelylow[362].Krogeretal.
investigated the eﬀect of DLI alone or in combination with s-
thalidomide, bortezomib, and lenalidomide in patients with
MMwhoachievedonlypartialremissionorverygoodpartial
remission after allogeneic stem cell transplantation [365].
Fifty-nine percent of patients achieved CR, and this CR re-
sulted in signiﬁcantly improved progression-free survival at
5 years (58% versus 35%). CR by ﬂow cytometry could be
achieved in 63%, and this resulted in an even more favorable
e v e n t - f r e es u r v i v a la t5y e a r s( 7 4 %v e r s u s1 5 % )[ 365].
18. Combined Donor Vaccination and
Allogeneic Stem-Cell Transplantation
A special aspect of active immunotherapy in MM is the com-
bination of alloSCT with the induction of myeloma-spe-
ciﬁc immunity in the donor’s immune system. The donor
immune system is presumably naive for the patient’s mye-
loma idiotype and therefore not tolerized or anergic. There-
fore, induction of tumor-speciﬁc immunity in donors of
haematopoietic stem cells for myeloma patients by idiotype
immunization, followed by adoptive transfer of speciﬁc im-
mune cells into the transplanted patient, may render allo-
geneic SCT from a nonspeciﬁc form of active immunother-
apy into a tumor-speciﬁc therapy. In the 38C13 mouse ly-
mphoma model, mice receiving marrow from a donor im-
munized with 38C13 idiotype had a statistically signiﬁcant
survival advantage after a lethal challenge with 38C13 lym-
phoma cells compared to animals transplanted with control
marrow [366]. When preimmunized marrow transplanta-
tionwascombinedwithasubsequentboosterimmunization,
even tumor-bearing mice could evidently be cured of their




related donors received three subcutaneous vaccinations
with idiotype (coupled to KLH at the 1st vaccination) and
GM-CSF prior to alloSCT. All donors developed cellular
and humoral anti-idiotype immune responses. After boneClinical and Developmental Immunology 15
marrow transplantation, the three patients who survived
longer than 30 days received 3 booster vaccinations with
KLH-coupled idiotype and GM-CSF. Remarkably, these
patients survived without evidence for disease recurrence for
5 . 5t om o r et h a n8y e a r s ,a n da l lh a de v i d e n c ef o r[ 367] idio-
type-speciﬁc immunity after alloSCT.
One recipient suﬀered from chronic GvHD and was on
chronic steroid therapy, while the other 2 recipients and all
of the donors were medically well, without any signiﬁcant
complications.
In order to avoid immunization of the healthy donor, at-
tempts have been made to generate myeloma idiotype-spec-
iﬁc donor immunity through in vitro stimulation of donor T
cells with monocyte-derived, idiotype-presenting DC [368].
Implementation of this approach would permit to extend the
principle of transfer of tumour-speciﬁc immunity to the vast
pool of unrelated stem cell donors for alloSCT.
19. Conclusions
MM continues to be an incurable disease with fatal outcome
for the majority of patients at advanced stages. Therefore,
exploration of novel therapeutic modalities should be pur-
sued.
Immunotherapy seems promising and may prove eﬀec-
tive in eradicating the malignant stem cell pool that is non-
proliferating and generally resistant to chemotherapy.
Various clinical immunotherapy treatment strategies
havebeentested.Mostofthesestrategieshavefocusedontar-
geting idiotype-speciﬁc immunity. Idiotype-based vaccines
have been shown in preclinical tests to induce or enhance
idiotype-speciﬁc immunity. But clinical response is rare, oc-
curring only in a minority of treated patients, suggesting that
the eﬀect is too weak to cause signiﬁcant tumor destruction.
Ideally, a tumor-speciﬁc immunotherapy should induce or
expand only the beneﬁcial immune responses mediated by
CTLs (Th1 and Tc1 subsets) that have suﬃcient cytotoxic
eﬀects toward tumor cells but not normal cells. Further stud-
ies are warranted so to better understand the immune re-
gulation mechanism in MM.
TSAs continue to be identiﬁed in myeloma, and a sys-
tematic assessment and comparisons to identify the most
promising candidates for clinical trials, are necessary. Vacci-
nation with DC/tumor fusions induces antitumor immunity
inamajorityofthepatients;however,responsesaretransient
and not always associated with clinical beneﬁt. One potential
limiting factor is the regulatory T cells. It is necessary to
develop ways to promote the expansion and increase the
amountoffunctionallycompetenttumor-reactiveTcellsand
to limit the inﬂuence of regulatory T cells in order to im-
prove the eﬃcacy of the DC/MM fusion vaccine. One ap-
proach is vaccination in conjunction with ASCT which faci-
litates vaccine response by inducing a minimal disease state
and limiting the inhibitory inﬂuence of the myeloma cells.
In preclinical models, stem cell transplantation results in
the in vivo depletion of regulatory T cells, transient loss of
tumor mediated tolerance, and enhanced capacity to re-
spond to tumor vaccines [167, 168]. Exposure to lenali-
domide increased cytotoxic T lymphocyte-mediated lysis
autologous tumor targets indicating of the potential of cel-
lular immunotherapy in conjunction with lenalidomide in-
cluding its use as part in the DC/myeloma fusion vaccine
[169].
Functionally potent DCs can be generatedby stimulation
with NK cells and may provide an eﬀective source of DC-
based immunotherapy in MM [174]. Modulation of inhibi-
tory and activating NK receptor ligands on tumor cells re-
presents a promising therapeutic approach against MM.
Perhaps the most interesting ﬁeld for active immuno-
therapy in myeloma lies in the combination with allogeneic
stem cell transplantation. This setting oﬀers the advantage
of an immune system that is unaﬀected by potential negative
inﬂuences exerted by the tumor on the immune system.
Transfer of tumor antigen-speciﬁc immunity from the donor
to the myeloma patient may help to enhance the immuno-
logical eﬃcacy of allogeneic SCT and to separate graft-ver-
sus-myeloma from graft-versus-host activity. The most cru-
cial question to develop this concept further is whether the
donor has to be immunized personally or whether eﬃca-
cious, speciﬁc antitumor immunity can be induced ex vivo
or in the transplanted patient.
MM exhibits a number of potentially valuable targets
for mAb therapy that await further investigation in clinical
studies. As has been the case with other cancers, mAbs, when
employed as monotherapy in MM, have generally not pro-
duced impressive levels of response with respect to either
response rates or extent of response in individual patients.
However, preclinical results in MM cell lines and murine
explant models and preliminary clinical results in patients
with relapsed/refractory MM suggest that mAbs are likely
to act synergistically with traditional therapies (dexametha-
sone), immune modulators (thalidomide, lenalidomide),
and other novel therapies (such as the ﬁrst-in-class protea-
some inhibitor bortezomib); in addition, mAbs have shown
the ability to overcome resistance to these therapies. These
observations suggest that future work may be most pro-
ductively directed at the rational development of multiagent
therapies incorporating speciﬁc mAbs on the basis of clinical
trial results and, possibly, on the identiﬁcation of patient-
speciﬁc MM disease factors. Indeed, many of the molecules
composing the surface proﬁle of plasma cells, such as CD38,
CD138, CD162, and CD49d, are involved in the adhesive
dynamics regulating the crosstalk between MM cells and the
BMstromalenvironment.Thesearchfornewtreatmentstra-
tegies to improve outcomes for MM patients has led to the
development of novel antibody-based therapies currently
undergoing clinical evaluation.
Major progress in understanding interactions between
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